Filing Flows › Certara (CERT) › Guidance & outlook
Certara (CERT) guidance and outlook
Certara (CERT) lowered its guidance on Nov 5, 2026: Revenue +2% to +3% for FY2026; EBITDA margin 29%–31% for FY2026; EPS $0.31–$0.34 for FY2026; Tax rate 25%–30% for FY2026. Certara's 10-Q filed Nov 5, 2026 makes 15 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +2% to +3% | reaffirmed |
| EBITDA margin | FY2026 | 29%–31% | reaffirmed |
| EPS | FY2026 | $0.31–$0.34 | lowered |
| Tax rate | FY2026 | 25%–30% | new |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Our services are delivered by scientists with extensive drug development experience who aid our customers in applying biosimulation and MIDD to their specific projects.
- We have worked with more than 2,600 life sciences companies and academic institutions and have collaborated on more than 10,000 customer projects in the last decade across a wide variety of therapeutic areas ranging from cancer and hematology to diabetes and hundreds of rare diseases.
- With continued innovation in and adoption of our biosimulation software, technology, and services, we believe more life science companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.
- We have invested and intend to continue to invest in expanding the breadth and depth of our solutions, including through acquisitions and international expansion.
- We expect to continue to invest in (i) scientific talent to expand our ability to deliver solutions across the drug development spectrum; (ii) sales and marketing to promote our solutions to new and existing customers and in existing and expanded geographies; (iii) research and development to support existing solutions and innovate new technology; (iv) other operational and administrative functions to support our…
- There has been a steady increase in the recognition by regulatory and academic institutions of the role that modeling and simulation can play in the biopharmaceutical development and approval process, as demonstrated by new regulations and guidance documents describing and encouraging the use of modeling and simulation in the biopharmaceutical discovery, development, testing, and approval process, which has…
- We believe that the presentation of the GAAP and the non-GAAP metrics in this filing will aid investors in understanding our business.
- Equity-based compensation has been, and we expect will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.
- We plan to continue to invest in sales and marketing to increase penetration of our existing client base and expand to new clients.
- We plan to continue to invest in our R&D efforts to enhance and scale our software product offerings by development of new features and increased functionality.
- We expect income tax expense to increase over time as the Company continues to grow more profitable.
- Our expected primary uses on a short-term and long-term basis are for repayment of debt, interest payments, working capital, capital expenditures, geographic or service offering expansion, acquisitions, investments, common stock repurchase and other general corporate purposes.
Certara's latest quarter
Certara, Q3 2026: revenue $94.9M (+4% year over year), operating margin 2.4%, net earnings $5.6M, operating cash flow $30.7M. The chart follows the revenue to costs, profit and cash.
Questions
Did Certara raise or lower its guidance?
Certara (CERT) lowered its guidance on Nov 5, 2026: Revenue +2% to +3% for FY2026; EBITDA margin 29%–31% for FY2026; EPS $0.31–$0.34 for FY2026; Tax rate 25%–30% for FY2026.
What does Certara expect?
Our services are delivered by scientists with extensive drug development experience who aid our customers in applying biosimulation and MIDD to their specific projects. We have worked with more than 2,600 life sciences companies and academic institutions and have collaborated on more than 10,000 customer projects in the last decade across a wide variety of therapeutic areas ranging from cancer and hematology to diabetes and hundreds of rare diseases. With continued innovation in and adoption of our biosimulation software, technology, and services, we believe more life science companies worldwi
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.